Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus

This observational study is following people in Belarus with chronic lymphocytic leukemia (CLL) — a slow-growing type of blood cancer — who are newly starting acalabrutinib as their sole treatment, to track how well it works and what side effects occur in routine clinical practice outside of a controlled trial. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of CLL - Your doctor has just prescribed acalabrutinib monotherapy (without other anti-leukemia drugs) within the past 4 weeks - You are either newly diagnosed (never been treated) or have received prior CLL treatment - You are willing and able to provide written informed consent - You are not currently participating in any other clinical trial **You may NOT be eligible if...** - You have previously been treated with any BTK inhibitor, including ibrutinib or zanubrutinib - You are taking other anti-leukemia medications at the same time as acalabrutinib - You are currently enrolled in another interventional clinical trial - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.